10-K: Johnson & Johnson Reports 2024 Annual Results: Revenue Up, Strategic Initiatives Progress

Sentiment:

Annual Results 13 February 2025 4:07 PM

Johnson & Johnson's 2024 annual report reveals a 4.3% increase in worldwide sales, driven by growth in both Innovative Medicine and MedTech segments, alongside strategic acquisitions and R&D investments.

Summary

Johnson & Johnson's worldwide sales increased by 4.3% to $88.8 billion in 2024.
The Innovative Medicine segment saw a 4.0% increase in sales, reaching $57.0 billion, while the MedTech segment experienced a 4.8% increase, totaling $31.9 billion.
U.S. sales grew by 8.3% to $50.3 billion, and international sales decreased slightly by 0.5% to $38.5 billion.
The company invested $17.2 billion in research and development, representing 19.4% of total sales.
Earnings before provision for taxes on income were $16.7 billion, or 18.8% of sales.
The company completed the acquisition of Shockwave Medical, Inc. on May 31, 2024, contributing to the MedTech segment's growth.
Biosimilar competition for STELARA is expected to impact sales in 2025.
The company is involved in ongoing litigation, including talc-related claims, with a reserve of approximately $11.6 billion.
The company is pursuing a consensual prepackaged Chapter 11 bankruptcy plan to resolve talc claims.
The company increased its dividend for the 62nd consecutive year, paying $4.91 per share in 2024.

Sentiment

Score: 7

Explanation: The document presents a balanced view with positive growth in revenue and strategic initiatives, but also highlights risks and challenges related to litigation and competition. The sentiment is moderately positive.

Positives

Strong sales growth in both Innovative Medicine and MedTech segments.
Significant investment in research and development to drive future innovation.
Strategic acquisitions, such as Shockwave Medical, enhance the MedTech portfolio.
Continued dividend increases demonstrate financial strength and commitment to shareholders.
Advancements in the pipeline with several regulatory submissions and approvals for new drugs and additional indications for existing drugs.
Strong sales of DARZALEX driven by continued share gains and market growth.
Growth of ERLEADA primarily due to continued share gains and market growth.
Sales of CARVYKTI driven by continued share gains, capacity expansion and manufacturing efficiencies.
Sales growth of both OPSUMIT and UPTRAVI was driven by market growth and share gains.

Negatives

Decline in international sales by 0.5%.
Biosimilar competition for STELARA is expected to impact sales in 2025.
Ongoing litigation, including talc-related claims, creates uncertainty and financial risk.
Decline of STELARA sales was driven by share loss primarily due to European biosimilar entrants.
Lower sales of REMICADE due to continued biosimilar competition.
Infectious disease products sales were down 23.1% primarily driven by a decline in COVID-19 vaccine revenue.
ZYTIGA sales were down due to loss of exclusivity and IMBRUVICA sales were down due to global competitive pressures.

Risks

Intense competition in the healthcare industry.
Potential delays and interruptions in manufacturing operations.
Reliance on third-party manufacturers and suppliers.
Counterfeit versions of products could harm patients and the company's reputation.
Global health crises, pandemics, epidemics, or other outbreaks could adversely disrupt or impact certain aspects of the company's business, results of operations and financial condition.
Global sales may be negatively impacted by healthcare reforms and increasing pricing pressures.
Increasing number of costly and complex governmental regulations.
Significant legal proceedings that can result in significant expenses, fines and reputational damage.
Product reliability, safety and effectiveness concerns.
Changes in tax laws or exposures to additional tax liabilities.
Increased challenges to intellectual property rights.
Significant challenges or delays in the company's innovation, development and implementation of new products, technologies and indications.
Financial, economic, legal, social and political risks associated with conducting business internationally.
Weak financial performance, failure to maintain a satisfactory credit rating or disruptions in the financial markets.
Inability to recruit and retain talented and highly skilled employees.
Climate change or legal, regulatory or market measures to address climate change.
An information security incident, including a cybersecurity breach.
A breach of privacy laws or unauthorized access, loss or misuse of personal data.

Future Outlook

The company expects continued launches of biosimilar versions of STELARA in Europe and the United States in 2025, which will impact the company's sales of STELARA.

Management Comments

Management is committed to creating life-enhancing innovations and value through partnerships.
Employees are empowered and inspired to lead with Our Credo and purpose as guides.
The Company can remain focused on addressing the unmet needs of society every day and invest for an enduring impact, ultimately delivering value to its patients, consumers and healthcare professionals, employees, communities and shareholders.

Industry Context

The healthcare industry is facing increasing pricing pressures and regulatory scrutiny, requiring companies to innovate and operate efficiently. Johnson & Johnson's strategic acquisitions and R&D investments position it to compete effectively in this evolving landscape.

Comparison to Industry Standards

Johnson & Johnson competes with companies of all sizes on the basis of cost-effectiveness, technological innovations, intellectual property rights, product performance, real or perceived product advantages, pricing and availability and rate of reimbursement.
Competitors include companies such as Pfizer, Novartis, Roche, and Medtronic.
The company's R&D spending as a percentage of sales is comparable to other major pharmaceutical and medical device companies.
The company's dividend yield is competitive with other dividend-paying stocks in the healthcare sector.

Legal Proceedings

The company is involved in numerous lawsuits and claims regarding product liability, intellectual property, commercial, employment, indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of business.
The company is pursuing a consensual prepackaged Chapter 11 bankruptcy plan to resolve talc claims.
The company is involved in ongoing litigation related to the marketing of opioids.
The company is involved in ongoing litigation related to the marketing of RISPERDAL.
The company is involved in ongoing litigation related to the marketing of ELMIRON.

Stakeholder Impact

Shareholders: Continued dividend payments and potential for long-term growth.
Employees: Commitment to employee health, well-being, and safety.
Customers: Access to innovative healthcare products and services.
Suppliers: Continued business relationships and potential for growth.
Creditors: Financial stability and ability to meet debt obligations.

Next Steps

Continue to pursue regulatory submissions and approvals for new drugs and additional indications for existing drugs.
Continue to monitor and manage the impact of biosimilar competition on STELARA sales.
Continue to defend against ongoing litigation, including talc-related claims.
Continue to pursue a consensual prepackaged Chapter 11 bankruptcy plan to resolve talc claims.
Continue to invest in research and development to drive future innovation.
Continue to monitor the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable.

Key Dates

Date	Description
1887	Johnson & Johnson was incorporated in the State of New Jersey.
September 15, 1987	Date of the Indenture between Johnson & Johnson and The Bank of New York Mellon Trust Company, N.A.
September 1, 1990	Date of the First Supplemental Indenture.
1995	United States Private Securities Litigation Reform Act of 1995.
November 9, 2017	Date of the Second Supplemental Indenture.
December 31, 2017	Date before which the Company has recorded deferred tax liabilities on all undistributed earnings from its international subsidiaries.
January 1, 2018	Date after which the Company has not provided deferred taxes on the undistributed earnings from certain international subsidiaries where the earnings are considered to be indefinitely reinvested.
January 1, 2018	Effective date of the reduction of the statutory corporate tax rate from 35% to 21% due to the U.S. Tax Cuts and Jobs Act (TCJA).
February 2019	Imerys Talc America, Inc. and two of its affiliates filed a voluntary petition for relief under Chapter 11 of the United States Code.
October 2021	Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring.
October 2021	LTL Management LLC filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under Chapter 11 of the Bankruptcy Code.
August 2022	President Biden signed into law the Inflation Reduction Act (IRA).
August 29, 2023	The Centers for Medicare & Medicaid Services (CMS) published the first Selected Drug list, which includes XARELTO and STELARA as well as IMBRUVICA.
May 8, 2023	Kenvue completed its initial public offering (IPO).
August 23, 2023	Johnson & Johnson completed the disposition of an additional 80.1% ownership of Kenvue Common Stock through an exchange offer.
July 2023	Janssen Pharmaceuticals, Inc. filed litigation against the U.S. Department of Health and Human Services and the Centers for Medicare and Medicaid Services challenging the constitutionality of the IRA's Medicare Drug Price Negotiation Program.
May 31, 2024	Johnson & Johnson completed the acquisition of Shockwave Medical Inc.
May 17, 2024	The Company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock for the outstanding Commercial Paper.
June 20, 2024	The Company completed the acquisition of Proteologix, Inc.
July 11, 2024	The Company completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics AG.
October 8, 2024	The Company completed the acquisition of V-Wave Ltd.
December 29, 2024	End of fiscal year 2024.
January 2, 2025	The Board of Directors declared a regular cash dividend of $1.24 per share, payable on March 4, 2025 to shareholders of record as of February 18, 2025.
February 6, 2025	There were 2,407,616,693 shares of Common Stock outstanding.

Keywords

Johnson & Johnson, financial results, annual report, Innovative Medicine, MedTech, sales, research and development, acquisitions, litigation, STELARA, DARZALEX, biosimilars, talc, dividends, pharmaceuticals, medical devices

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.